UMike
Klutzing in Re-Thai-erment
- Joined
- 16 January 2007
- Posts
- 1,650
- Reactions
- 2,098
With the Trump effect I am confident there is more down side to come.
CSL - CSL Limited
- Thread starter kaisong
- Start date
-
- Tags
- csl csl limited
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
down < 1 percent... above $253
CSL has reassured investors that pharmaceutical products are not subject to a baseline import tariff announced by the US administration, but said it was assessing the broader impact of the new measures.
The US administration imposed a 10 per cent baseline levy on all countries’ exports and an array of country-specific levies on jurisdictions including China, the EU and Vietnam.
CSL manufacturers some pharmaceutical products in Germany and Switzerland and imports some products to the US from those facilities.
The biotech told investors on Thursday all pharmaceutical products were not subject to reciprocal tariffs. It did not address the Trump administration’s new 20 per cent levy on imports from the EU.
“At this stage pharmaceutical products are not subject to the reciprocal tariffs. CSL is continuing to assess the broader impact of the tariffs and will monitor further announcements by the US government,” it said
Knobby22
Mmmmmm 2nd breakfast
- Joined
- 13 October 2004
- Posts
- 10,616
- Reactions
- 8,276
Actually gone up.
Port in a storm. (one of my yearly picks).
Port in a storm. (one of my yearly picks).
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
Captured
Hold on tight.
Kind regards
rcw1
Hold on tight.
Kind regards
rcw1
@Knobby22 ... not for rcw1... 476th away from capture ha ha ha ha ha maybe
View attachment 195508
View attachment 195507
- Joined
- 21 November 2007
- Posts
- 209
- Reactions
- 398
Good luck but it's an uphill battle paying that sort of brokerage in and out.
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
yes, a good discipline to not overtrade, I'd imagine
Good evening
AFR
Apr 7, 2025 – 3.37pm
CSL and some of the country’s other big pharmaceutical companies could be targeted in any expansion of the Trump administration’s tariffs, Health Minister Mark Butler has warned, after Australian medicines were left out of the sweeping trade barriers announced by the White House late last week. His comments came as Australian healthcare stocks were caught up in a global sharemarket rout on concerns that the US tariffs would drive up costs. The chief executives of two of Australia’s biggest ASX-listed biotechs warned that Trump administration policies were driving investors away.
Butler said the US tariff plan was an act of “self-harm” against American patients, and that trade officials, including Australia’s ambassador to the United States, former prime minister Kevin Rudd, were still working to understand the full implications of the imposts.
Pharmaceuticals have been a point of contention between the Trump administration and Australia. American drug manufacturing companies complain about slow access to the local market and say the Pharmaceutical Benefits Scheme often subsidises cheaper generic products over theirs.
Butler told the Financial Review Healthcare Summit on Monday that briefings from US officials suggested foreign pharmaceuticals could soon be targeted by a separate trade investigation under the Trump administration’s powers to build up domestic manufacturing and protect national security.
“Some backgrounding suggested it might be within weeks. So we’re watching that very closely,” Butler told the audience in Sydney. “We will continue to work for exemption and a better treatment. We don’t think this is the act of a friend and don’t think it reflects the mutual benefit that has come from decades now of free and fair trade between our countries.”
The vast majority of the $1.6 billion in pharmaceutical products exported to the US last year were manufactured at CSL’s plant in Melbourne. The blood and plasma products are fractionated – the process of separating whole blood into its individual components – at the plant in Broadmeadows.
A CSL spokesman said it was continuing to monitor announcements by the US and declined to comment on speculation around any future tariffs.
“This is going to be a pretty significant act in self-harm for the Americans,” Butler said. “They’re going to just pay more for stuff they can’t substitute in any short-term sense. This is not in the interests of American patients.”
Cochlear chief executive Dig Howitt said it was still unclear if his company’s products manufactured in Australia and China and exported to the US would be exempt or not. Cochlear shares have fallen 7 per cent since Friday.
“Historically, we’ve been exporting to the US and under a certain category that has been exempt in the past. So we will see,” Howitt said. “From an Australian perspective, we’ve got to make sure that we are one of the best places to do business in the world, so that whatever happens around us, we can continue to succeed in a very competitive global environment.”
Silviu Itescu, the founding chief executive of cell therapy maker Mesoblast, warned global turmoil would make life more difficult for biotechnology companies seeking to raise capital from skittish investors.
“Global turmoil is never good. Uncertainty is never good. There is turmoil at the [Food and Drug Administration], people have left, they’re understaffed, and I think that creates uncertainty. We need certainty, particularly in high-risk industries. And biotech is a high-risk industry,” Itescu said.
Mesoblast shares fell 8.5 per cent on Monday.
Alan Taylor, the chief executive of ASX-listed Clarity Pharmaceuticals, said he was concerned about the impact Trump administration policies were having on investor confidence in biotechs.
Clarity shares have lost 80 per cent of their value since November.
“It’s about confidence, and if you don’t have confidence in the market, suddenly you’re down 5 per cent and then the next day and the next day. Our hope is that there’s some common sense that prevails,” Taylorsaid.
In a foreign trade barrier report last week, the US Trade Representative reiterated long-standing complaints about the PBS, a program through which the government buys drugs in bulk at a discount.
Last week, David Ricks, the chief executive of American pharmaceutical giant Eli Lilly, complained that it took too long for the PBS to approve breakthrough drugs. For instance, women have had to wait up to two years to have access to cutting-edge breast cancer drugs as approvals have dragged out.
Butler said the local medicine industry and patients also wanted faster approvals, and this would be one of his priorities in a second-term Labor government by implementing the health technology review.
“The scale and the complexity of new therapies coming on to the market are jaw-dropping,” he said. “We do need a fit-for-purpose, agile system of assessment, approval, reimbursement, and we have something that was built for a different era. We share the ambitions to deliver that change.”
But he said Labor would continue to defend the core elements of the PBS and would not compromise on that. “We want to engage with the Americans to get the best outcome for American companies, American consumers. We’re not willing to negotiate some of those core design elements of PBS, but I do want to see quicker access.”
AFR
Butler expects tariff pain on medicines and healthcare giants
John Kehoe and Michael SmithApr 7, 2025 – 3.37pm
CSL and some of the country’s other big pharmaceutical companies could be targeted in any expansion of the Trump administration’s tariffs, Health Minister Mark Butler has warned, after Australian medicines were left out of the sweeping trade barriers announced by the White House late last week. His comments came as Australian healthcare stocks were caught up in a global sharemarket rout on concerns that the US tariffs would drive up costs. The chief executives of two of Australia’s biggest ASX-listed biotechs warned that Trump administration policies were driving investors away.
Butler said the US tariff plan was an act of “self-harm” against American patients, and that trade officials, including Australia’s ambassador to the United States, former prime minister Kevin Rudd, were still working to understand the full implications of the imposts.
Pharmaceuticals have been a point of contention between the Trump administration and Australia. American drug manufacturing companies complain about slow access to the local market and say the Pharmaceutical Benefits Scheme often subsidises cheaper generic products over theirs.
Butler told the Financial Review Healthcare Summit on Monday that briefings from US officials suggested foreign pharmaceuticals could soon be targeted by a separate trade investigation under the Trump administration’s powers to build up domestic manufacturing and protect national security.
“Some backgrounding suggested it might be within weeks. So we’re watching that very closely,” Butler told the audience in Sydney. “We will continue to work for exemption and a better treatment. We don’t think this is the act of a friend and don’t think it reflects the mutual benefit that has come from decades now of free and fair trade between our countries.”
The vast majority of the $1.6 billion in pharmaceutical products exported to the US last year were manufactured at CSL’s plant in Melbourne. The blood and plasma products are fractionated – the process of separating whole blood into its individual components – at the plant in Broadmeadows.
A CSL spokesman said it was continuing to monitor announcements by the US and declined to comment on speculation around any future tariffs.
“This is going to be a pretty significant act in self-harm for the Americans,” Butler said. “They’re going to just pay more for stuff they can’t substitute in any short-term sense. This is not in the interests of American patients.”
Higher costs to be passed on
Medtech products were not exempted from the initial 10 per cent tariffs on Australia imposed by Trump last week, affecting several ASX-listed companies – from hearing aid producer Cochlear to gloves manufacturer Ansell and respiratory treatments business ResMed.Cochlear chief executive Dig Howitt said it was still unclear if his company’s products manufactured in Australia and China and exported to the US would be exempt or not. Cochlear shares have fallen 7 per cent since Friday.
“Historically, we’ve been exporting to the US and under a certain category that has been exempt in the past. So we will see,” Howitt said. “From an Australian perspective, we’ve got to make sure that we are one of the best places to do business in the world, so that whatever happens around us, we can continue to succeed in a very competitive global environment.”
Silviu Itescu, the founding chief executive of cell therapy maker Mesoblast, warned global turmoil would make life more difficult for biotechnology companies seeking to raise capital from skittish investors.
“Global turmoil is never good. Uncertainty is never good. There is turmoil at the [Food and Drug Administration], people have left, they’re understaffed, and I think that creates uncertainty. We need certainty, particularly in high-risk industries. And biotech is a high-risk industry,” Itescu said.
Mesoblast shares fell 8.5 per cent on Monday.
Alan Taylor, the chief executive of ASX-listed Clarity Pharmaceuticals, said he was concerned about the impact Trump administration policies were having on investor confidence in biotechs.
Clarity shares have lost 80 per cent of their value since November.
“It’s about confidence, and if you don’t have confidence in the market, suddenly you’re down 5 per cent and then the next day and the next day. Our hope is that there’s some common sense that prevails,” Taylorsaid.
In a foreign trade barrier report last week, the US Trade Representative reiterated long-standing complaints about the PBS, a program through which the government buys drugs in bulk at a discount.
Last week, David Ricks, the chief executive of American pharmaceutical giant Eli Lilly, complained that it took too long for the PBS to approve breakthrough drugs. For instance, women have had to wait up to two years to have access to cutting-edge breast cancer drugs as approvals have dragged out.
Butler said the local medicine industry and patients also wanted faster approvals, and this would be one of his priorities in a second-term Labor government by implementing the health technology review.
“The scale and the complexity of new therapies coming on to the market are jaw-dropping,” he said. “We do need a fit-for-purpose, agile system of assessment, approval, reimbursement, and we have something that was built for a different era. We share the ambitions to deliver that change.”
But he said Labor would continue to defend the core elements of the PBS and would not compromise on that. “We want to engage with the Americans to get the best outcome for American companies, American consumers. We’re not willing to negotiate some of those core design elements of PBS, but I do want to see quicker access.”
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
and here it is...
CSL down 5 percent
US president Donald Trump says he is preparing to announce a “major” tariff on pharmaceuticals in an expansion of his damaging trade war that would hit $1.6 billion in annual Australian exports.
“We are going to tariff our pharmaceuticals and once we do that they’re going to come rushing back into our country because we’re the big market,” Trump said in a televised address to the National Republican Congressional Committee on Wednesday.
.
.
The vast majority of the $1.6 billion in pharmaceutical products exported to the US last year were manufactured at CSL’s plant in Melbourne. The blood and plasma products are fractionated – the process of separating whole blood into its individual components – at the plant in Broadmeadows.
“We are going to tariff our pharmaceuticals and once we do that they’re going to come rushing back into our country because we’re the big market,” Trump said in a televised address to the National Republican Congressional Committee on Wednesday.
Money, money, money, can't stop thinking about it! What next?
Fundamentally, what has changed in CSL? But we can't look at that alone anymore.. The whole landscape has changed.
Money, money, money, can't stop thinking about it! What next?
Fundamentally, what has changed in CSL? But we can't look at that alone anymore.. The whole landscape has changed.
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
Now that TDS (Tariff Disruption Shock) has been around since late 2nd April, as expected certain sectors are doing better than others.
today's close $233.62
today's close $233.62
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
- but on a dollar value?
tariffs will be messy, probably unfocused and likely to favour the US corporations
Sean K
Moderator
- Joined
- 21 April 2006
- Posts
- 23,360
- Reactions
- 13,789
This has been going up and down between 250 and 300 for 5 years.
What's going on? Has it just growthed out, no more plasma to buy?
Maybe they need to diversify into pharmacies or hospitals or?
What's going on? Has it just growthed out, no more plasma to buy?
Maybe they need to diversify into pharmacies or hospitals or?
- Joined
- 8 June 2008
- Posts
- 14,670
- Reactions
- 22,252
It is not a growth stock yet older shareholders still think it is, as it has been for so long...good on them
Should be a blue chip with a bit of currency coverage and some decent dividends.
From memory, dividends are still lagging
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
my dividend yield is close to 60 percent pa on invested money
.
if you pay my capital gains tax, I'll happily sell
oh, and suggest something else too
Sean K
Moderator
- Joined
- 21 April 2006
- Posts
- 23,360
- Reactions
- 13,789
Did you mistakenly put a zero next to that 6?
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,010
- Reactions
- 27,542
- Joined
- 8 June 2008
- Posts
- 14,670
- Reactions
- 22,252
Good on you and exactly what i pointed:
You got into a growth share, were successful.
But it is not growing today, i do not care nor should anyone ,5y or 10y ago:
today, it is not a dividend share, nor a growth one
Now do you happily reinvest all your dividends into CSL?
if not why?
if CSL falls seriously today, i might start getting in, as i would with Telstra, not as i would with a startup
- Joined
- 8 June 2008
- Posts
- 14,670
- Reactions
- 22,252
galumay
learner
- Joined
- 17 September 2011
- Posts
- 3,661
- Reactions
- 2,541
I understand you thinking with yield on invested capital, but more realistic is to consider what the yield is on the capital you would end up with after tax if you sold. That way you can compare the opportunity cost of continuing to hold.
It may well be that its better to hold even with a comparatively low yield because of the tax cost of selling and the problem of finding another company to invest in.
I am always very reluctant to sell out of a great business, its often fool's gold to sell down or out of your big winners, but I do think its an error to think of yield on invested money, its a similar cognitive error to the idea of "free carry".
